Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial by Murphy, PB et al.
Effect of HomeNoninvasive VentilationWith Oxygen Therapy
vs Oxygen Therapy Alone on Hospital Readmission or Death
After an Acute COPD Exacerbation
A Randomized Clinical Trial
Patrick B. Murphy, PhD; Sunita Rehal, MSc; Gill Arbane, BSc (Hons); Stephen Bourke, PhD; Peter M. A. Calverley, PhD; Angela M. Crook, PhD;
Lee Dowson, MD; Nicholas Duffy, MD; G. John Gibson, MD; Philip D. Hughes, MD; John R. Hurst, PhD; Keir E. Lewis, MD; Rahul Mukherjee, MD;
Annabel Nickol, PhD; Nicholas Oscroft, MD; Maxime Patout, MD; Justin Pepperell, MD; Ian Smith, MD; John R. Stradling, PhD;
Jadwiga A. Wedzicha, PhD; Michael I. Polkey, PhD; MarkW. Elliott, MD; Nicholas Hart, PhD
IMPORTANCE Outcomes after exacerbations of chronic obstructive pulmonary disease
(COPD) requiring acute noninvasive ventilation (NIV) are poor and there are few treatments
to prevent hospital readmission and death.
OBJECTIVE To investigate the effect of home NIV plus oxygen on time to readmission or
death in patients with persistent hypercapnia after an acute COPD exacerbation.
DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial of patients with persistent
hypercapnia (PaCO2 >53mmHg) 2 weeks to 4 weeks after resolution of respiratory acidemia,
who were recruited from 13 UK centers between 2010 and 2015. Exclusion criteria included
obesity (bodymass index [BMI] >35), obstructive sleep apnea syndrome, or other causes of
respiratory failure. Of 2021 patients screened, 124 were eligible.
INTERVENTIONS There were 59 patients randomized to home oxygen alone (median oxygen
flow rate, 1.0 L/min [interquartile range {IQR}, 0.5-2.0 L/min]) and 57 patients to home
oxygen plus home NIV (median oxygen flow rate, 1.0 L/min [IQR, 0.5-1.5 L/min]). Themedian
home ventilator settings were an inspiratory positive airway pressure of 24 (IQR, 22-26) cm
H2O, an expiratory positive airway pressure of 4 (IQR, 4-5) cmH2O, and a backup rate of 14
(IQR, 14-16) breaths/minute.
MAIN OUTCOMES ANDMEASURES Time to readmission or death within 12months adjusted for
the number of previous COPD admissions, previous use of long-term oxygen, age, and BMI.
RESULTS A total of 116 patients (mean [SD] age of 67 [10] years, 53% female, mean BMI of
21.6 [IQR, 18.2-26.1], mean [SD] forced expiratory volume in the first second of expiration of
0.6 L [0.2 L], andmean [SD] PaCO2 while breathing room air of 59 [7] mmHg) were
randomized. Sixty-four patients (28 in home oxygen alone and 36 in home oxygen plus home
NIV) completed the 12-month study period. Themedian time to readmission or death was
4.3 months (IQR, 1.3-13.8 months) in the home oxygen plus home NIV group vs 1.4 months
(IQR, 0.5-3.9 months) in the home oxygen alone group, adjusted hazard ratio of 0.49 (95%
CI, 0.31-0.77; P = .002). The 12-month risk of readmission or death was 63.4% in the home
oxygen plus home NIV group vs 80.4% in the home oxygen alone group, absolute risk
reduction of 17.0% (95% CI, 0.1%-34.0%). At 12 months, 16 patients had died in the home
oxygen plus home NIV group vs 19 in the home oxygen alone group.
CONCLUSIONS AND RELEVANCE Among patients with persistent hypercapnia following an
acute exacerbation of COPD, adding home noninvasive ventilation to home oxygen therapy
prolonged the time to readmission or death within 12 months.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00990132
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C hronic obstructive pulmonary disease (COPD) is char-acterized by recurrent exacerbations that can cause in-termittentperiodsofsevereclinicaldeteriorationrequir-
ing hospitalization and ventilator support. Although treating
patients with COPD and acute respiratory failure with nonin-
vasive ventilation improves outcomes,1,2 persistent hypercap-
nia after an exacerbation is associatedwith excessmortality3,4
and early rehospitalization.5 In 2013, the 28-day COPD read-
mission rate was around 20%,6 and there were financial pen-
alties inplace in theUnitedKingdomandUnitedStates for such
early readmissions. These data have contributed to readmis-
sion prevention being a priority area for clinicians.
One treatment optionwould be to use noninvasive venti-
lation inaddition tooxygen therapy in thehomesetting. Small,
uncontrolled studies demonstrating the physiological effi-
cacyofhomenoninvasiveventilation inpatientswithCOPD7-9
have led to its prescription across Europe.10 However, subse-
quent clinical studies failed todemonstrate either physiologi-
cal (reduced hypercapnia) or clinical (mortality) efficacy,11,12
andquestions remain regardingwhether theapplicationof the
interventionwasoptimized in these randomizedclinical trials.
The lackof improvement inchronic respiratory failuremay
explain the failure of earlier trials,13 which is a theory sup-
ported by data from Köhnlein et al14 that demonstrated both
improvementof chronic respiratory failure andamortality re-
duction. However, the participants in this trial were atypical
of most patients with severe COPD and had relatively pre-
served exercise capacity and a low exacerbation and hospital
admission rate,which limits the clinical applicability of these
findings. In contrast, the Respiratory Support in COPD after
Acute Exacerbation (RESCUE) trial,15 which targeted patients
with frequent exacerbations, failed to demonstrate a clinical
benefit of homenoninvasive ventilationwhen added to stan-
dard care.
In thismulticenter randomized clinical trial conducted in
theUnitedKingdom, itwas hypothesized that the addition of
homenoninvasive ventilation tohomeoxygen therapywould
prolong the time to readmissionordeath amongpatientswith
persistenthypercapnia following anacute life-threatening ex-
acerbation of COPD requiring acute noninvasive ventilation.
Methods
Trial Design and Patients
The trialwasaphase3,multicenter, open-label, parallel-group
randomized clinical trial with a 1:1 allocation to home oxygen
therapyaloneorhomenoninvasiveventilationplushomeoxy-
gen therapy. The trialwas approvedbyStThomas’Hospital re-
search ethics committee (09/H0802/2) and by local research
and development committees at participating centers. All re-
cruitedpatientsprovidedwritten informedconsentandall trial
procedures conformed to local policies. The trial protocol and
statistical analysis plan appear in Supplement 1.
Patients were recruited from 13 UK centers and were fol-
lowedup for 12months. Patients admittedwith acute decom-
pensatedhypercapnic exacerbations of COPD requiring acute
noninvasive ventilationwere screened for eligibility at least 2
weeks after resolutionof decompensated acidosis (arterial pH
>7.30) and within 4 weeks of attaining clinical stability
(eMethods in Supplement 2). Patients were required to have
persistent hypercapnia (PaCO2 >53 mm Hg) and hypoxemia
(PaO2 <55mmHg or <60mmHg; ≥1 of polycythemia, pulmo-
naryhypertension, or cor pulmonale; >30%of sleep timewith
oxygen saturation<90%asmeasuredbypulse oximetry); and
arterial pH greater than 7.30 while breathing room air.
Arterial blood gas analysis was performed after at least 1
night without noninvasive ventilation support and after re-
ceiving oxygen therapy overnight. Chronic respiratory fail-
urewasattributed to severeCOPDprovided that the forcedex-
piratoryvolume in the first secondofexpiration (FEV1)was less
than 50%of predicted, the ratio of FEV1 to forced vital capac-
ity was less than 60%, and the patient had a smoking history
of greater than20pack-years andwas in theabsenceof (1) obe-
sity (body mass index [calculated as weight in kilograms di-
vided by height in meters squared] >35), (2) clinically signifi-
cant obstructive sleepapnea syndrome (if clinically suspected
by attending physician from history, examination, or base-
line oximetry, it was then investigated with attended limited
respiratory polygraphy; eMethods in Supplement 2), and
(3) neuromuscular or chest wall disease.
Patients were excluded if they (1) were not assessed
within 4 weeks of resolution of the index COPD exacerbation,
(2) required intubation and invasive mechanical ventilation
during the index exacerbation, (3) were currently using non-
invasive home mechanical ventilation, (4) exhibited cogni-
tive impairment or unstable psychiatric morbidity, (5) were
undergoing renal replacement therapy, (6) had active
unstable coronary artery syndrome, (7) were younger than 18
years, and (8) were homeless. Additional exclusion criteria
appear in Figure 1.
Eligible patientswere transferred for assessment to a spe-
cialist noninvasiveventilation center if theymet theabovecri-
teriaduring the indexadmissionandwithin the time frameaf-
ter discharge or transfer.
Randomization andMasking
Patients were randomized by the Oxford Clinical Trials Unit
using computer-basedminimization software (Minim).Mini-
mization summates the imbalance within each stratification
variable if apatient is allocated toaparticular treatmentgroup,
Key Points
Question Does the addition of home noninvasive ventilation
to home oxygen therapy prolong time to readmission or death
for patients with chronic obstructive pulmonary disease and
persistent hypercapnia following a life-threatening exacerbation?
Findings In this randomized clinical trial of 116 patients, the
addition of home noninvasive ventilation significantly prolonged
time to readmission or death from 1.4months to 4.3 months.
Meaning The addition of home noninvasive ventilation to home
oxygen therapymay improve outcomes in patients with severe
chronic obstructive pulmonary disease and persistent hypercapnia
following hospital admission.
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and the next treatment to be randomized is chosen depend-
ing on which treatment would minimize the imbalance.16
Theminimizationcriteriawereage (<65yearsvs≥65years),
body mass index (≤20 vs >20), current long-term oxygen
therapy use (yes vs no), frequency of COPD-related readmis-
sions during previous 12 months (<3 vs ≥3), and recruitment
center. Although there was no suitable sham option for non-
invasive ventilation, and the supervising clinicians were un-
blinded to treatment allocation, the trial staff conducting the
outcome assessments were blinded to treatment allocation.
Intervention
Noninvasiveventilationwas initiatedusingnasal, oronasal, or
total facemasks per patient preference. Noninvasive ventila-
tionwasdeliveredusing theHarmony2ventilator (PhilipsRes-
pironics) or theVPAP IIISTaventilator (ResMed)witheachcen-
ter restricted to a single model. Patients underwent daytime
noninvasive ventilation acclimatization, followed by noctur-
nal titration with oxygen entrained at the daytime prescrip-
tion rate (eMethods and eAppendix 1 in Supplement 2). The
aimwas to achieve control of nocturnal hypoventilationwith
a high-pressure ventilation strategy.17
Inbothpatient groups, oxygen therapywas initiatedat the
lowest flow rate required to increase the PaO2 level to greater
than 60 mm Hg without producing decompensated respira-
tory failure, which was defined as an arterial pH of less than
7.30 on the morning blood gas measurement after overnight
use of oxygen without noninvasive ventilation. All patients
were instructedtouseoxygentherapyforat least 15hoursdaily.
Thepatientsallocated tohomeoxygentherapyplushomenon-
invasive ventilation were instructed to use the ventilator for
a minimum of 6 hours nightly.
All patientshadmedicalmanagementoptimized forCOPD
according toguidelines fromtheBritishThoracicSociety18 that
included regular, triple-inhaledbronchodilator therapy (long-
acting β-agonist, long-acting antimuscarinic, and steroid), as-
needed inhaled short-acting β-agonist therapy, sputumclear-
ance techniques where appropriate, smoking cessation
support, and education on COPD self-management. Patients
allocated to home oxygen therapy alone could receive acute
noninvasive ventilation during hospital readmissions for de-
compensated respiratory failure with the intention of being
weanedanddischargedback tooxygenaloneunless therewas
a breach in the safety criteria (eMethods in Supplement 2).
Outcome and Assessments
Theprimaryoutcomewas time to readmissionordeathwithin
12 months after randomization (ie, time from randomization
Figure 1. Participant FlowDiagram
2021 Patients assessed for eligibility
116 Randomized
59 Included in primary analysis57 Included in primary analysis
0 Lost to follow-up
13 Withdrew
0 Lost to follow-up
5 Withdrew
59 Randomized to receive home oxygen
therapy alone
59 Received intervention as
randomized
18 Home noninvasive ventilation
added to oxygen therapy
during triald
57 Randomized to receive home
oxygen therapy plus home
noninvasive ventilation
56 Received intervention as
randomized
1 Did not receive intervention
as randomized (declined)
1905 Excluded
419 Arterial blood gas levels did not meet
inclusion criteriaa
252 Unable to wean from noninvasive
ventilation (pH <7.30)
237 Unable to provide consent 
157 Admission not due to an acute
exacerbation of chronic obstructive
pulmonary disease
131 Unable to tolerate noninvasive ventilation
128 Died prior to screening
96 Body mass index >35b
76 Had obstructive sleep apnea
51 Post decannulation or extubation during
index admission
46 Unable to complete assessment within 4 wk
of resolution of exacerbation
8 Decompensated with oxygen therapyc
8 Eligible but not randomized due to
clinician preference
296 Refused to participate a Defined as absence of hypercapnia
(PaCO2 <53mmHg), hypoxemia
(PaO2 >60mmHg), or both.
bCalculated as weight in kilograms
divided by height in meters
squared.
c Defined as an arterial pH of less
than 7.30whenmorning arterial
blood gas measured after use of
oxygen therapy alone.
d Seventeen patients received home
noninvasive ventilation after
hospital readmission (consistent
with trial protocol) and, at the
discretion of the treating clinician,
1 patient received home noninvasive
ventilation prior to reaching the
primary outcome.
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to either hospital readmission or death from any cause). Pa-
tients readmittedto thehospitalprior tostudywithdrawalwere
censored at the time of hospital readmission. Patients who
withdrewwere censored at the time of studywithdrawal and
were considered as not meeting the primary end point. Any
patients who were readmitted to the hospital prior to with-
drawal were censored at the time of the hospital readmis-
sion. Baseline descriptive data were recorded in line with lo-
cal and national guidelines and included collection of
anthropometric data, sex (self-reported), and spirometry and
arterial blood gas analysis.
Secondary exploratory outcomes included all-cause mor-
tality, exacerbation frequency (exacerbation defined in
eMethods, eAppendix 1, and eAppendix 2 in Supplement 2),
change in arterial PaCO2 and PaO2 while breathing room air,
change in control of sleep-disordered breathing (as measured
by4%oxygendesaturation index,meannocturnaloxygensatu-
rationasmeasuredbypulseoximetry, total sleeptimewithoxy-
gensaturationasmeasuredbypulseoximetry<90%,meannoc-
turnal transcutaneouscarbondioxide,andmaximumnocturnal
transcutaneous carbon dioxide), breathlessness as measured
using theMedical Research Council dyspnea score19 (categori-
cal scale from 1-5; higher scores indicate more limitations on
daily activitiesdue tobreathlessness), health-relatedqualityof
lifemeasuredusing theSevereRespiratory InsufficiencyQues-
tionnaire (0 = worst quality of life, 100 = best quality of life),20
and the St George’s Respiratory Questionnaire (0 = best qual-
ityof life, 100 = worstqualityof life;minimally important clini-
cal difference of 4)21,22 at each follow-up assessment.
Hospital readmission and exacerbation data were col-
lected at each follow-up visit (6 weeks, 3 months, 6 months,
and 12months) and vital status at trial completionwas estab-
lishedusing theNationalHealthService informationcenter for
patients lost to follow-up.We performed sensitivity analyses
on the primary outcome to assess for robustness post hoc.
Sample Size Calculation and Statistical Analysis
The sample sizewasbasedonUKaudit data (M.W.Elliott,MD,
Department of Respiratory Medicine, Leeds University Hos-
pital, oral communication,2008), assuminga readmission rate
of 55% at 12 months in patients after an admission requiring
treatment with noninvasive ventilation for an acute exacer-
bation of COPD. If home noninvasive ventilation reduced re-
admissions to 25% at 12 months, and assuming a loss to
follow-up of 22%, 116 patients would be needed to provide
80% power with a 2-sided significance level of .05.
Data are presented as mean (standard deviation) or me-
dian (interquartile range [IQR]) as appropriate.All primaryand
secondaryanalyseswereassessedfor superiorityandwereana-
lyzed according to the intention-to-treat principle, including
all randomized patients in whom an outcome was available.
The primary outcome defined as time from randomization to
hospital readmission or death was analyzed using a Cox pro-
portional hazards regression model adjusted for minimiza-
tion variables (age, body mass index, current long-term oxy-
gen therapy use, frequency of COPD readmissions over 12
months). Toavoidoverstratification, recruiting centerwasnot
included in the adjusted model.23
Sensitivity analyses using best-case and worst-case sce-
narioswereperformedposthoc to assess the robustnessof the
primaryoutcomeanalysis.Thebest-case scenarioassumedpa-
tients who withdrewwere neither readmitted to the hospital
nor died and were censored 12 months after randomization.
Theworst-case scenarioassumedpatientswhowithdrewwere
readmitted to the hospital or died and were censored at the
point of withdrawal. These analyses explore the most ex-
treme scenarios for patients who withdrew prior to reaching
the primary end point.
Other post hoc analyses included time to hospital read-
mission28days after randomization andwere analyzedusing
a Cox proportional hazards regression model for comparison
withprevious studies. Theper-protocol analysis excludedpa-
tients (1) who switched treatment during the trial prior to
achieving the primary end point and (2) whose average daily
use of noninvasive ventilation was less than 4 hours. Addi-
tional analyses included center as a fixed effect and as a ran-
dom effect, with the latter being a post hoc analysis. Unad-
justed hazard ratios (HRs) for treatment effects are also
presented. Full details appear in the statistical analysis plan
in Supplement 1.
All-cause mortality was analyzed using a Cox propor-
tional hazards regression model. A post hoc analysis of the
number of exacerbations per year was performed using (1)
negative binomial regression due to clustering of exacerba-
tions within patients and (2) linear mixed-effects regression
models with a random effect for center to assess continuous
variables. Statistical significancewas concludedat the2-sided
significance level of .05 for all analyses.All analyseswere con-
ducted using Stata software version 14.1 (StataCorp).
Results
Patients
Of the 2021 patients screened, 124 were eligible, and 116 pa-
tients were randomized between February 27, 2010, and
April 6, 2015 (Figure 1). Therewere 57 patients randomized to
homeoxygen therapyplus homenoninvasive ventilation and
59 patients to home oxygen therapy alone. The final patient
visit occurred on April 23, 2016. Sixty-four patients (28 in the
home oxygen therapy alone group and 36 in the home oxy-
gen therapy plus home noninvasive ventilation group) com-
pleted the 12-month study period.
Eighteen patients withdrew from the study, 12 before
reaching the primary outcome (10 patients in the home oxy-
gentherapyalonegroupand2 in thehomeoxygentherapyplus
homenoninvasive ventilation group). Seventeenpatients ini-
tially randomized to receive home oxygen therapy alone had
home noninvasive ventilation added after reaching the pri-
mary outcomeof readmission,whichwas consistentwith the
trial protocol (eMethods in Supplement 2).
At the discretion of the treating clinician (on trial day 2)
and prior to reaching the primary outcome, 1 patient random-
ized to the home oxygen therapy alone group was instructed
to add home noninvasive ventilation but remained in the
home oxygen therapy group for analysis purposes. Baseline
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characteristics appear in Table 1. The groups were well bal-
anced for important baseline variables, including minimiza-
tion factors. The randomized cohort had severe COPD as
evidenced by severe airflow obstruction (mean [SD] FEV1
of 0.6 L [0.2 L] and mean [SD] ratio of FEV1 to forced vital
capacity of 0.4 [0.1]) and hypercapnia respiratory failure
(mean [SD] PaCO2 of 59 [7] mmHg). There was no evidence of
significant obstructive sleep apnea in randomized patients
(eTable 1 in Supplement 2).
The dropout rate was within the prespecified power cal-
culation and the retention and follow-up numbers appear in
eTable2 inSupplement2.Themedian follow-up timewas 12.2
months (IQR, 8.9-12.9 months) for the home oxygen therapy
plushomenoninvasiveventilationgroupand8.1months (IQR,
2.3-12.6 months) for the home oxygen therapy alone group.
Intervention
There was no significant between-group difference in the
oxygen therapy flow rates after baseline titration (median
oxygen flow rate, 1.0 L/min [IQR, 0.5-2.0 L/min] for the home
oxygen therapy alone group vs 1.0 L/min [IQR, 0.5-1.5 L/min]
for the home oxygen therapy plus home noninvasive ventila-
tion group; P = .11).
Themedianventilator settings at hospital discharge in the
homeoxygentherapyplushomenoninvasiveventilationgroup
werean inspiratorypositiveairwaypressureof24cmH2O(IQR,
22-26 cmH2O), an expiratorypositive airwaypressure of 4 cm
H2O (IQR, 4-5 cm H2O), and a backup rate of 14 breaths/
minute (IQR, 14-16 breaths/minute). Ventilator use at 6weeks
was 4.7 hours per night (IQR, 2.5-5.6 hours per night), which
increased during the trial to 7.6 hours per night (IQR, 3.6-8.4
hours per night) at 12 months (eTable 3 in Supplement 2).
Delivery and Efficacy of HomeNoninvasive Ventilation
There was a statistically significant reduction in nocturnal
transcutaneous carbon dioxide levels on the night after ini-
tiation of noninvasive ventilation, which persisted to 12
months; however, at 6months the between-group difference
was not statistically significant (adjusted mean difference,
−0.63 kPa [95% CI, −1.55 to 0.30 kPa], P = .18; eTable 4 in
Supplement 2).
Therewas a statistically significant between-groupdiffer-
ence in daytime PaCO2 at 6 weeks and 3 months favoring the
home oxygen therapy plus home noninvasive ventilation
group, but not at 12months. Therewas no corresponding im-
provement in oxygenation (Table 2).
Table 1. Baseline Characteristics
Home Oxygen Therapy Plus
NIV (n = 57)
Home Oxygen Therapy
Alone (n = 59)
Total
(N = 116)
Age, mean (SD), ya 66.4 (10.2) 67.1 (9.0) 66.7 (9.6)
Body mass index, median (IQR)a,b 21.5 (18.8-24.5) 22.2 (17.9-26.9) 21.6 (18.2-26.1)
Prior use of long-term oxygen therapy, No. (%)a 40 (70) 40 (68) 80 (69)
≥3 COPD-related readmissions within past year, No. (%)a 30 (53) 31 (53) 61 (53)
Female sex, No. (%) 29 (51) 32 (54) 61 (53)
Smoking history, median (IQR), pack-years 42.0 (30.5-60.0) 45.0 (31.0-55.0) 44.0 (31.0-60.0)
Apnea Hypopnea Index, median (IQR), /hc 2.4 (0.9-6.2) 2.0 (0.8-3.9) 2.2 (0.8-5.1)
Neck circumference, median (IQR), cm 36.3 (33.0-40.0) 38.6 (35.3-41.0) 37.0 (34.5-40.0)
Waist circumference, median (IQR), cm 90.0 (78.0-100.5) 87.5 (78.0-106.0) 88.0 (78.0-102.0)
FEV1, mean (SD), L 0.6 (0.2) 0.6 (0.2) 0.6 (0.2)
FEV1 % predicted, mean (SD) 24.0 (8.6) 22.9 (8.6) 23.4 (8.6)
Forced vital capacity, mean (SD), L 1.8 (0.8) 1.5 (0.6) 1.7 (0.7)
Forced vital capacity % predicted, mean (SD) 57.4 (19.7) 49.3 (20.4) 53.2 (20.4)
Ratio of FEV1 to forced vital capacity, mean (SD) 0.3 (0.1) 0.4 (0.1) 0.4 (0.1)
PaO2 while breathing room air, mean (SD), mm Hg 48 (9) 48 (8) 48 (8)
PaCO2 while breathing room air, mean (SD), mm Hg 59 (7) 59 (7) 59 (7)
Arterial pH while breathing room air, mean (SD) 7.40 (0.04) 7.40 (0.03) 7.40 (0.04)
St George’s Respiratory Questionnaire summary score,
median (IQR)d
74.7 (63.7-81.7) 71.0 (62.6-78.6) 73.8 (63.3-80.3)
Severe Respiratory Insufficiency Questionnaire summary score,
mean (SD)e
45.8 (15.0) 46.9 (15.6) 46.4 (15.2)
Medical Research Council dyspnea score, median (IQR)f 5.0 (4.0-5.0) 5.0 (4.0-5.0) 5.0 (4.0-5.0)
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in the first second of expiration; IQR, interquartile range;
NIV, noninvasive ventilation.
a Minimization variable used during the randomization process to enhance the
chance of creating balanced groups.
b Calculated as weight in kilograms divided by height in meters squared.
c There were 25 patients in the home oxygen therapy plus home
noninvasive mechanical ventilation group and 19 in the home oxygen therapy
alone group.
dOn a scale of 0 to 100 in which 0 is the best quality-of-life score and
100 is the worst.
e On a scale of 0 to 100 in which 100 is the best quality-of-life score and
0 is the worst.
f On a categorical scale of 1 to 5; higher scores indicate more limitation on daily
activities due to breathlessness.
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Primary Outcome: Time to Readmission or Death
The median time to readmission or death was 4.3 months
(IQR, 1.3-13.8months) in thehomeoxygen therapyplus home
noninvasive ventilation group compared with 1.4 months
(IQR,0.5-3.9months) in thehomeoxygen therapyalonegroup
(Figure 2). For readmission or death within 12 months, there
was an adjusted HR of 0.49 (95% CI, 0.31-0.77; P = .002) and
an unadjusted HR of 0.54 (95% CI, 0.34-0.84; P = .007). The
12-month risk of readmissionor deathwas63.4% in thehome
oxygen therapyplushomenoninvasiveventilationgroupcom-
pared with 80.4% in the home oxygen therapy alone group,
resulting in an absolute risk reductionof 17.0% (95%CI, 0.1%-
34.0%).
The per-protocol and sensitivity analyses also were
consistent with these results (eResults and eTable 5 in
Supplement2).Aposthocanalysisof28-dayreadmission iden-
tified a significant treatment effect with an unadjusted HR of
0.27 (95%CI, 0.12-0.63; P = .003) and an adjustedHR of 0.26
(95% CI, 0.11-0.61; P = .002) (eFigure in Supplement 2). The
majority of readmissions during follow-upwere related to re-
spiratory concerns (201/209 readmissions).
All-CauseMortality
Asimilarnumberofpatients inbothtreatmentgroupsdieddur-
ing the event triggeringprimaryoutcomecompletion (5 in the
homeoxygentherapyplushomenoninvasiveventilationgroup
and 4 in the home oxygen therapy alone group). Twelve-
monthmortalitywasnotsignificantlydifferentbetweengroups
(16patients [28%] in thehomeoxygen therapyplushomenon-
invasiveventilationgroupvs19patients [32%] in thehomeoxy-
gen therapy alone group; unadjusted HR, 0.68 [95%CI, 0.35-
1.32], P = .26; adjusted HR, 0.67 [95% CI, 0.34-1.30], P = .23)
with most causes of death being respiratory (eTable 6 in
Supplement 2).
Acute COPD Exacerbation Frequency
There was a reduction in the COPD exacerbation rate in the
homeoxygentherapyplushomenoninvasiveventilationgroup
(median, 3.8 exacerbations per year [IQR, 1.7-6.0 exacerba-
tionsperyear]) comparedwith thehomeoxygen therapyalone
group (median, 5.1 exacerbations per year [IQR, 1.0-9.2 exac-
erbations per year]; unadjusted rate ratio, 0.64 [95%CI, 0.44-
0.94], P = .02; adjusted rate ratio, 0.66 [95% CI, 0.46-0.95],
P = .03; eTable 7 in Supplement 2).
Health-Related Quality of Life
At 6 weeks, the Severe Respiratory Insufficiency Question-
naire mean score was 50.6 in the home oxygen therapy plus
homenoninvasiveventilationgroupand49.2 in thehomeoxy-
gen therapy alone group with an unadjusted between-group
difference of 4.85 (95% CI, 0.43-9.27; P = .03) and an ad-
justed between-group difference of 4.48 (95% CI, 0.02-8.94;
P = .05), indicating improved health-related quality of life in
the home oxygen therapy plus home noninvasive ventilation
group at this time point.
At 3 months, the St George’s Respiratory Questionnaire
mean score was 62.9 in the home oxygen therapy plus home
noninvasiveventilationgroupcomparedwith66.0 in thehomeTa
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oxygen therapy alone groupwith a significant unadjusted be-
tween-group difference of −4.30 (95% CI, −8.39 to −0.21;
P = .04) and a significant adjusted between-group difference
of −4.85 (95% CI, −8.83 to −0.88; P = .02), indicating a ben-
eficial effect of home noninvasive ventilation on health-
related quality of life at this time point. Therewere no signifi-
cant differences demonstrated thereafter (Table 3).
Discussion
In this randomizedclinical trial, an improvement in time to re-
admissionordeathwasobservedwhenhomenoninvasiveven-
tilation was added to home oxygen therapy in patients with
persistent hypercapnia following a life-threatening acute ex-
acerbation of COPD. These data support the screening of pa-
tients with COPD after receiving acute noninvasive ventila-
tion to identify persistent hypercapnia and introduce home
noninvasive ventilation.
The current data differ from the RESCUE trial,15 even
though the trial designs were similar. The RESCUE trial
showed no difference in time to readmission or death within
12 months. Differences in the study population and protocol
may explain the discordant results because the RESCUE
trial15 enrolled patients with a less stringent PaCO2 criterion
(daytime PaCO2 >45 mm Hg) following cessation of acute
noninvasive ventilation, whereas the current trial only
recruited patients if the daytime PaCO2 was greater than
53 mm Hg at least 2 weeks after resolution of acute respira-
tory acidemia. Furthermore, and unlike the RESCUE trial,15
the current study also required demonstration of chronic
hypoxemia and thus targeted patients with more severe
COPD. Such patients with chronic respiratory failure have
previously been shown to benefit from noninvasive ventila-
tion in physiological studies.7,9
The early, within-hospital assessment of hypercapnia
in the RESCUE trial may have led to the inclusion of patients
with spontaneously reversible hypercapnia and conse-
quently a better prognosis.24 Consistent with this conjecture,
the control group as well as the treatment noninvasive venti-
lation group of the RESCUE study showed a reduction in
daytime PaCO2 within 6 weeks of enrollment,15 supporting
the rationale that the trajectory of recovery for hypercapnia
determines the likelihood of response to home noninvasive
ventilation. However, the improvement in hypercapnia dem-
onstrated could be accounted for by regression to the mean
rather than a truephysiological effect. Basedonpreviousdata
from the investigators,17 the current trial protocol adopted a
high-pressure titration strategywith ademonstratedeffect on
nocturnal hypoventilation.
Despite the delay in time to readmission or death with
enhanced control of nocturnal ventilation and reduced exac-
erbation frequency, there was only an initial modest effect
on health-related quality of life with the addition of home
noninvasiveventilation.This isperhapsunsurprisinggiven the
severity of disease in the COPD cohort enrolled and the high
levels of physical impairment at baseline. The results of the
current trial are reassuring, suggesting that home noninva-
sive ventilation added to home oxygen therapy in this popu-
lation improved the overall clinical outcome without adding
to the health burden of the patient, countering earlier con-
cerns raised by the Australian trial of Non-invasive Ventila-
tion in Chronic Airflow Limitation.12
The participant flow diagram (Figure 1) shows that 2021
patientswere screenedandconsideredeligible for the trial.Al-
though only 6% of screened patients were recruited into the
trial, one-third of the screened patients were ineligible be-
cause they could eithernotwean fromacutenoninvasiveven-
tilation due to clinical instability, they died prior to screen-
ing, or they were unable to provide consent. These factors
highlight that this was a cohort of patients with severe dis-
ease, contributing to the recruitment rate observed. The pro-
cess of assessing the patients during the recovery phase, and
only recruiting those patients with a PaCO2 of greater than
53mmHg, helped to ensure the cohortwas enrichedwith pa-
tientswithchronic respiratory failure,which is thecohortmost
Figure 2. Kaplan-Meier Survival Plot of Time to Readmission or Death FromRandomization to the End of Trial
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likely to benefit from the addition of home noninvasive ven-
tilation therapy.
Patients with established chronic respiratory failure sec-
ondarytoCOPDhavepooroutcomeswith limitedtreatmentop-
tionsavailable.3,4 Thedriverof the clinical improvement in the
homeoxygentherapyplushomenoninvasiveventilationgroup
was readmission avoidance with no significant difference in
mortalityobservedbetween the treatmentgroupand the stan-
dard carehomeoxygen therapy alone group for both the event
triggering theprimaryoutcomeandat 12months.However, the
studywasnotpowered todetect adifference for this outcome.
This study has major clinical relevance because readmission
avoidance is beneficial to the patient in terms of preservation
of lung function and health-related quality of life25 as well as
providing a direct and indirect cost saving.
The results of this study support the use of in-home,
high-pressure noninvasive ventilation in patients who have
persistent hypercapnia for 2 to 4 weeks after resolution of
respiratory acidemia requiring acute noninvasive ventilation.
There are physiological mechanisms that underpin the effect
of home noninvasive ventilation when added to home oxy-
gen therapy that could explain the clinical benefit of reduced
hospital readmission. Previous physiological studies have
shown that home noninvasive ventilation in patients with
severe COPD improves ventilatory response to hypercapnia,7
which could be expected to act as a clinically relevant effect
of treatment, allowing a more robust and adaptive response
to the adverse physiological challenge of an acute PaCO2
increase during an exacerbation.
Furthermore, imagingdatasuggest thathigh-pressurenon-
invasive ventilationmay contribute to airway remodeling and
improvedventilation-perfusionmatching.26 Inaddition, theob-
servation of an improvement in gas exchangewith a reduction
in PaCO2 and exacerbation frequency is supported by data that
have shown that hypercapnia decreases secretion of IL-6 and
tumor necrosis factor in the lungs and impairs lungneutrophil
function inananimalmodel of lung infection.27 Futureexperi-
ments are required to investigate this observation.
Limitations
This study has a number of limitations. First, the lack of a
double-blind design for this trial is a potential criticism.
The use of a sham device group was considered because this
approachhasbeenusedpreviously in continuouspositive air-
waypressure trials in patientswithobstructive sleep apnea.28
However, the use of a device modified to deliver zero pres-
sure support through a nasal or face mask could result in
an increase in dynamic dead space,29 which would have the
potential to worsen respiratory failure. In addition, sham
continuouspositive airwaypressure can affect sleep architec-
ture, the clinical significance of which is unknown.30 There
was further concern regarding the effectiveness of blinding in
sham device trials because both patients and clinicians have
been able to identify the sham intervention, limiting the sci-
entific justification of this approach.31,32 The unblinded trial
design and lack of a shamdevice, with blinded assessment in
terms of the outcome, is consistent with other clinical trials
in this field.11,12,14,15Ta
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Second, the trial designwaspragmatic in that itmadepro-
vision for patients initially allocated to home oxygen therapy
to have homenoninvasive ventilation added if they breached
safety criteria after reaching the primary outcome. Eighteen
patients initially allocated to homeoxygen therapy alone had
home noninvasive ventilation added to their management
strategy. In 17 of 18 cases (94%), the addition of home nonin-
vasive ventilation occurred after the primary end point was
reached, thus not affecting the primary analysis. This proto-
col design may have contributed to the apparent dilution of
treatment effect of homenoninvasive ventilation on daytime
hypercapnia, nocturnal hypoventilation, andquality of life af-
ter 3months becausehomenoninvasive ventilationhadbeen
addedby this timepoint to the treatmentofmore thanhalf the
remaining patients in the home oxygen therapy alone group.
Third, the statistical analysis plan for the study included
a number of secondary outcomes that should be considered
exploratorybecausenocorrectionswereusedformultiplecom-
parisons. The secondary outcomes were included to provide
mechanistic support for the primary outcome. The use of a
single level of significance for secondary outcomes is consis-
tent with other data in this area.14,15
Conclusions
Amongpatientswithpersistenthypercapnia followinganacute
exacerbation of COPD, adding home noninvasive ventilation
tohomeoxygen therapyprolonged the time to readmissionor
death within 12 months.
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